Post-Infarct Biomaterials, Left Ventricular Remodeling, and Heart Failure: Is Good Good Enough?

Congestive Heart Failure

Volumn 18, Issue 5, 2012, Pages 284-290

  Zouein, Fouad A ^a   Zgheib, Carlos ^a   Liechty, Kenneth W ^a   Booz, George W ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMATERIAL; CHITOSAN; HYALURONIC ACID;

ANGIOGENESIS; ARTICLE; DISEASE COURSE; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE REMODELING; HEART MUSCLE COMPLIANCE; HEART MUSCLE REPERFUSION; HUMAN; HYDROGEL; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SURVIVAL RATE; THERAPY EFFECT; THICKNESS;

ANTIHYPERTENSIVE AGENTS; BIOCOMPATIBLE MATERIALS; DISEASE PROGRESSION; HEART FAILURE; HUMANS; HYDROGELS; MYOCARDIAL INFARCTION; PROGNOSIS; TIME FACTORS; VENTRICULAR REMODELING;

EID: 84866558930     PISSN: 15275299     EISSN: 17517133     Source Type: Journal    
DOI: 10.1111/j.1751-7133.2012.00298.x     Document Type: Article

References (62)

1. Taming a killer. Heart attacks aren't nearly as deadly as they used to be. Harv Heart Lett. 2010;20:5.
2. Bernheim SM, Grady JN, Lin Z, et al. National patterns of risk-standardized mortality and readmission for acute myocardial infarction and heart failure. Update on publicly reported outcomes measures based on the 2010 release. Circ Cardiovasc Qual Outcomes. 2010;3:459-467.
3. Krumholz HM, Merrill AR, Schone EM, et al. Patterns of hospital performance in acute myocardial infarction and heart failure 30-day mortality and readmission. Circ Cardiovasc Qual Outcomes. 2009;2:407-413.
4. Gorman RC, Jackson BM, Burdick JA, Gorman JH. Infarct restraint to limit adverse ventricular remodeling. J Cardiovasc Transl Res. 2011;4:73-81.
5. Gheorghiade M, Bonow RO. Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation. 1998;97:282-289.
6. Yankey GK, Li T, Kilic A, et al. Regional remodeling strain and its association with myocardial apoptosis after myocardial infarction in an ovine model. J Thorac Cardiovasc Surg. 2008;135:991-998.
7. Wilson EM, Moainie SL, Baskin JM, et al. Region and type specific induction of matrix metalloproteinases in post myocardial infarction remodeling. Circulation. 2003;107:2857-2863.
8. Mann DL. Mechanisms and models in heart failure - A combinatorial approach. Circulation. 1999;100:999-1008.
9. Tiyyagura SR, Pinney SP. Left ventricular remodeling after myocardial infarction: past, present, and future. Mt Sinai J Med. 2006;73:840-851.
10. Koh MB, Suck G. Cell therapy: Promise fulfilled? Biologicals. 2012 Mar 8. [Epub ahead of print].
11. Hoover-Plow J, Gong Y. Challenges for heart disease stem cell therapy. Vasc Health Risk Manag. 2012;8:99-113.
12. Bolli R, Chugh AR, D'Amario D, et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet. 2011;378:1847-1857.
13. Weir RA, McMurray JJ, Velazquez EJ. Epidemiology of heart failure and left ventricular systolic dysfunction after acute myocardial infarction: prevalence, clinical characteristics, and prognostic importance. Am J Cardiol. 2006;97:13F-25F.
14. Nelson DM, Ma Z, Fujimoto KL, et al. Intra-myocardial biomaterial injection therapy in the treatment of heart failure: Materials, outcomes and challenges. Acta Biomater. 2011;7:1-15.
15. Tous E, Purcell B, Ifkovits JL, Burdick JA. Injectable acellular hydrogels for cardiac repair. J Cardiovasc Transl Res. 2011;4:528-542.
16. Gupta KB, Ratcliffe MB, Fallert MA, et al. Changes in passive mechanical stiffness of myocardial tissue with aneurysm formation. Circulation. 1994;89:2315-2326.
17. Holmes JW, Borg TK, Covell JW. Structure and mechanics of healing myocardial infarcts. Annu Rev Biomed Eng. 2005;7:223-253.
18. Pfeffer MA, Pfeffer JM. Ventricular enlargement and reduced survival after myocardial infarction. Circulation. 1987;75:IV93-IV97.
19. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation. 1990;81:1161-1172.
20. Schwinger RH, Böhm M, Koch A, et al. The failing human heart is unable to use the Frank-Starling mechanism. Circ Res. 1994;74:959-969.
21. Tonnessen T, Knudsen CW. Surgical left ventricular remodeling in heart failure. Eur J Heart Fail. 2005;7:704-709.
22. Jones RH, Velazquez EJ, Michler RE, et al. STICH Hypothesis 2 Investigators. Coronary bypass surgery with or without surgical ventricular reconstruction. N Engl J Med. 2009;360:1705-1717.
23. Sartipy U, Albage A, Lindblom D. The Dor procedure for left ventricular reconstruction. Ten-year clinical experience. Eur J Cardiothorac Surg. 2005;27:1005-1010.
24. Batista R. Partial left ventriculectomy - the Batista procedure. Eur J Cardiothorac. 1999;15:S12-S19.
25. Starling RC, Jessup M, Oh JK, et al. Sustained benefits of the CorCap Cardiac Support Device on left ventricular remodeling: three year follow-up results from the Acorn clinical trial. Ann Thorac Surg. 2007;84:1236-1242.
26. Klodell CT Jr, Aranda JM Jr, McGiffin DC, et al. Worldwide surgical experience with the Paracor HeartNet cardiac restraint device. J Thorac Cardiovasc Surg. 2008;135:188-195.
27. Gummert JF, Rahmel A, Bossert T, Mohr FW. Socks for the dilated heart. Does passive cardiomyoplasty have a role in long-term care for heart failure patients? Z Kardiol. 2004;93:849-854.
28. Blom AS, Pilla JJ, Gorman RC III, et al. Infarct size reduction and attenuation of global left ventricular remodeling with the CorCap cardiac support device following acute myocardial infarction in sheep. Heart Fail Rev. 2005;10:125-139.
29. Fukamachi K, McCarthy PM. Initial safety and feasibility clinical trial of the myosplint device. J Card Surg. 2005;20:S43-S47.
30. Kashem A, Kashem S, Santamore WP, et al. Early and late results of left ventricular reshaping by passive cardiac-support device in canine heart failure. J Heart Lung Transplant. 2003;22:1046-1053.
31. Mukherjee R, Zavadzkas JA, Saunders SM, et al. Targeted myocardial microinjections of a biocomposite material reduces infarct expansion in pigs. Ann Thorac Surg. 2008;86:1268-1276.
32. Leor J, Tuvia S, Guetta V, et al. Intracoronary injection of in situ forming alginate hydrogel reverses left ventricular remodeling after myocardial infarction in Swine. J Am Coll Cardiol. 2009;54:1014-1023.
33. Dai W, Wold LE, Dow JS, Kloner RA. Thickening of the infarcted wall by collagen injection improves left ventricular function in rats: a novel approach to preserve cardiac function after myocardial infarction. J Am Coll Cardiol. 2005;46:714-719.
34. Christman KL, Fok HH, Sievers RE, et al. Fibrin glue alone and skeletal myoblasts in a fibrin scaffold preserve cardiac function after myocardial infarction. Tissue Eng. 2004;10:403-409.
35. Kofidis T, Lebl DR, Martinez EC, et al. Novel injectable bioartificial tissue facilitates targeted, less invasive, large-scale tissue restoration on the beating heart after myocardial injury. Circulation. 2005;112:I173-I177.
36. Landa N, Miller L, Feinberg MS, et al. Effect of injectable alginate implant on cardiac remodeling and function after recent and old infarcts in rat. Circulation. 2008;117:1388-1396.
37. Huang NF, Yu J, Sievers R, et al. Injectable biopolymers enhance angiogenesis after myocardial infarction. Tissue Eng. 2005;11:1860-1866.
38. Tsur-Gang O, Ruvinov E, Landa N, et al. The effects of peptide-based modification of alginate on left ventricular remodeling and function after myocardial infarction. Biomaterials. 2009;30:189-195.
39. Wang T, Wu DQ, Jiang XJ, et al. Novel thermosensitive hydrogel injection inhibits post-infarct ventricle remodelling. Eur J Heart Fail. 2009;11:14-19.
40. Yoon SJ, Fang YH, Lim CH, et al. Regeneration of ischemic heart using hyaluronic acid-based injectable hydrogel. J Biomed Mater Res B Appl Biomater. 2009;91:163-171.
41. Yu J, Christman KL, Chin E, et al. Restoration of left ventricular geometry and improvement of left ventricular function in a rodent model of chronic ischemic cardiomyopathy. J Thorac Cardiovasc Surg. 2009;137:180-187.
42. Christman KL, Vardanian AJ, Fang Q, et al. Injectable fibrin scaffold improves cell transplant survival, reduces infarct expansion, and induces neovasculature formation in ischemic myocardium. J Am Coll Cardiol. 2004;44:654-660.
43. Ifkovits JL, Tous E, Minakawa M, et al. Injectable hydrogel properties influence infarct expansion and extent of postinfarction left ventricular remodeling in an ovine model. Proc Natl Acad Sci USA. 2010;107:11507-11512.
44. Arslan F, de Kleijn DP, Pasterkamp G. Innate immune signaling in cardiac ischemia. Nat Rev Cardiol. 2011;8:292-300.
45. Venugopal JR, Prabhakaran MP, Mukherjee S, et al. Biomaterial strategies for alleviation of myocardial infarction. J R Soc Interface. 2012;9:1-19.
46. Kofidis T, de Bruin JL, Hoyt G, et al. Injectable bioartificial myocardial tissue for large-scale intramural cell transfer and functional recovery of injured heart muscle. J Thorac Cardiovasc Surg. 2004;128:571-578.
47. Yu J, Gu Y, Du KT, et al. The effect of injected RGD modified alginate on angiogenesis and left ventricular function in a chronic rat infarct model. Biomaterials. 2009;30:751-756.
48. Zhu H, Fan GC. Role of microRNAs in the reperfused myocardium towards post-infarct remodelling. Cardiovasc Res. 2012;94:284-292.
49. Chung C, Beecham M, Mauck RL, Burdick JA. The influence of degradation characteristics of hyaluronic acid hydrogels on in vitro neocartilage formation by mesenchymal stem cells. Biomaterials. 2009;30:4287-4296.
50. Toole BP. Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer. 2004;4:528-539.
51. Khetan S, Burdick J. Cellular encapsulation in 3D hydrogels for tissue engineering. J Vis Exp. 2009; pii: 1590, doi: 10.3791/1590.
52. Sahoo S, Chung C, Khetan S, Burdick JA. Hydrolytically degradable hyaluronic acid hydrogels with controlled temporal structures. Biomacromolecules. 2008;9:1088-1092.
53. Khetan S, Chung C, Burdick JA. Tuning hydrogel properties for applications in tissue engineering. Conf Proc IEEE Eng Med Biol Soc. 2009;2009:2094-2096.
54. Kim IY, Seo SJ, Moon HS, et al. Chitosan and its derivatives for tissue engineering applications. Biotechnol Adv. 2008;26:1-21.
55. Roughley P, Hoemann C, DesRosiers E, et al. The potential of chitosan-based gels containing intervertebral disc cells for nucleus pulposus supplementation. Biomaterial. 2006;27:388-396.
56. Lu WN, Lü SH, Wang HB, et al. Functional improvement of infarcted heart by co-injection of embryonic stem cells with temperature-responsive chitosan hydrogel. Tissue Eng Part A. 2009;15:1437-1447.
57. Wang T, Jiang XJ, Lin T, et al. The inhibition of postinfarct ventricle remodeling without polycythaemia following local sustained intramyocardial delivery of erythropoietin within a supramolecular hydrogel. Biomaterials. 2009;30:4161-4167.
58. Jiang XJ, Wang T, Li XY, et al. Injection of a novel synthetic hydrogel preserves left ventricle function after myocardial infarction. J Biomed Mater Res A. 2009;90:472-477.
59. Fujimoto KL, Ma Z, Nelson DM, et al. Synthesis, characterization and therapeutic efficacy of a biodegradable, thermoresponsive hydrogel designed for application in chronic infarcted myocardium. Biomaterials. 2009;30:4357-4368.
60. Dobner S, Bezuidenhout D, Govender P, et al. A synthetic non-degradable polyethylene glycol hydrogel retards adverse post-infarct left ventricular remodeling. J Card Fail. 2009;15:629-636.
61. Rane AA, Chuang JS, Shah A, et al. Increased infarct wall thickness by a bio-inert material is insufficient to prevent negative left ventricular remodeling after myocardial infarction. PLoS ONE. 2011;6:e2157.
62. Kurdi M, Chidiac R, Hoemann C, et al. Hydrogels as a platform for stem cell delivery to the heart. Congest Heart Fail. 2010;16:132-135.